0001209191-23-026079.txt : 20230428 0001209191-23-026079.hdr.sgml : 20230428 20230428172447 ACCESSION NUMBER: 0001209191-23-026079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230404 FILED AS OF DATE: 20230428 DATE AS OF CHANGE: 20230428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schaefer Thomas J. CENTRAL INDEX KEY: 0001960808 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37383 FILM NUMBER: 23868461 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE STE 105 CITY: DAVIS STATE: CA ZIP: 95618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] IRS NUMBER: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: X1 ZIP: 95618 BUSINESS PHONE: 530-756-7077 MAIL ADDRESS: STREET 1: 202 COUSTEAU PLACE STREET 2: SUITE 105 CITY: DAVIS STATE: CA ZIP: 95618 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-04 0 0001469443 Arcadia Biosciences, Inc. RKDA 0001960808 Schaefer Thomas J. C/O ARCADIA BIOSCIENCES, INC. 5950 SHERRY LANE, SUITE 215 DALLAS TX 75225 0 1 0 0 Chief Financial Officer 0 Stock Option (Right to Buy) 7.55 2023-04-04 4 A 0 1500 0.00 A 2033-04-04 Common Stock 1500 5475 D The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs. Thomas J. Schaefer, by Attorney-in-fact, Solaeta Chan 2023-04-28 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Matthew Connor and Solaeta Chan, signing singly, the undersigned's true and lawful attorney-in-fact to: (i) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Arcadia Biosciences, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto), and for the purpose of filing such Forms, to execute and deliver any documents necessary to the Securities and Exchange Commission ("SEC") for the purpose of obtaining EDGAR codes, all in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations promulgated thereunder; (ii) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4 or 5 and timely file such form (including amendments thereto) with the SEC and any stock exchange or similar authority; and (iii) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned agrees that such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined in the first paragraph hereof as of a later date. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of March, 2023. /s/ Thomas J. Schaefer ___________________________ Signature Thomas J. Schaefer ___________________________ Print Name